Safety reports on the off-label use of baclofen for alcohol-dependence: recommendations to improve causality assessment

References

• Mirijello A, Caputo F, Vassallo G, et al. GABAB agonists for the treatment of alcohol use disorder. Curr Pharm Des. 2015;21(23):3367–3372.
   PubMed Web of Science ®Google Scholar
• Dupouy J, Fournier J-P, Jouanjus E, et al. Baclofen for alcohol dependence in France: incidence of treated patients and prescription patterns-a cohort study. Eur Neuropsychopharmacol. 2014;24(2):192–199.
   PubMed Web of Science ®Google Scholar
• Rolland B, Paille F, Fleury B, et al. Off-label baclofen prescribing practices among French alcohol specialists: results of a national online survey. PloS One. 2014;9(6):e98062.
   PubMed Web of Science ®Google Scholar
• Rolland B, Bordet R, Cottencin O. Alcohol-dependence: the current French craze for baclofen. Addiction. 2012;107(4):848–849.
   PubMed Web of Science ®Google Scholar
• Ameisen O. Complete and prolonged suppression of symptoms and consequences of alcohol-dependence using high-dose baclofen: a self-case report of a physician. Alcohol Alcohol. 2005;40(2):147–150.
   PubMed Web of Science ®Google Scholar
• Bucknam W. Suppression of symptoms of alcohol dependence and craving using high-dose baclofen. Alcohol Alcohol. 2007;42(2):158–160.
   PubMed Web of Science ®Google Scholar
• Pastor A, Jones DML, Currie J. High-dose baclofen for treatment-resistant alcohol dependence. J Clin Psychopharmacol. 2012;32(2):266–268.
   PubMed Web of Science ®Google Scholar
• Rigal L, Alexandre-Dubroeucq C, De Beaurepaire R, et al. Abstinence and ‘low-risk’ consumption 1 year after the initiation of high-dose baclofen: a retrospective study among ‘high-risk’ drinkers. Alcohol Alcohol. 2012;47(4):439–442.
   PubMed Web of Science ®Google Scholar
• De Beaurepaire R. Suppression of alcohol dependence using baclofen: a 2-year observational study of 100 patients. Front Psychiatry. 2012;3:103. doi:10.3389/fpsyt.2012.00103.
   PubMedGoogle Scholar
• De Beaurepaire R. The use of very high-doses of baclofen for the treatment of alcohol-dependence: a case series. Front Psychiatry. 2014;5:143. doi:10.3389/fpsyt.2014.00143.
   PubMed Web of Science ®Google Scholar
• BACLOVILLE study (NCT01604330). Baclofen for the treatment of alcohol drinkers. 2012 [cited 2016 Feb 10]. Available from: http://clinicaltrials.gov/ct2/show/NCT01604330
   Google Scholar
• ALPADIR study (NCT01738282). Efficacy and safety of baclofen for maintenance of abstinence in alcohol dependent patients. 2012 [cited 2016 Feb 10]. Available from: http://clinicaltrials.gov/show/NCT01738282.
   Google Scholar
• Rolland B, Mann K, Paille F, et al. The new French guidelines on alcohol misuse: an initiative for strengthening cross-European interplay. Addiction. 2015;110(8):1362–1363.
   PubMed Web of Science ®Google Scholar
• Müller CA, Geisel O, Pelz P, et al. High-dose baclofen for the treatment of alcohol dependence (BACLAD study): a randomized, placebo-controlled trial. Eur Neuropsychopharmacol. 2015;25(8):1167–1177.
   PubMed Web of Science ®Google Scholar
• Akosile W, Klan M. Creating a new problem: the use of baclofen in the management of alcohol use disorder. Drug Alcohol Rev. 2015. doi:10.1111/dar.12306.
   PubMed Web of Science ®Google Scholar
• Saddichha S, Jayaram N, Manjunatha N, et al. Baclofen-induced morbiliform rashes: a case series. J Clin Pharmacol. 2011;51(12):1733–1734.
   PubMed Web of Science ®Google Scholar
• Holla B, Gowda GS, Prabhu L, et al. High doses of baclofen as suicide attempt in patients with alcohol use disorders - a serious concern. Asian J Psychiatry. 2015;17:99–100. doi:10.1016/j.ajp.2015.06.015.
   PubMed Web of Science ®Google Scholar
• Rolland B, Labreuche J, Duhamel A, et al. Baclofen for alcohol dependence: relationships between baclofen and alcohol dosing and the occurrence of major sedation. Eur Neuropsychopharmacol. 2015;25(10):1631–1636.
   PubMed Web of Science ®Google Scholar
• Meyboom RH, Hekster YA, Egberts AC, et al. Causal or casual? The role of causality assessment in pharmacovigilance. Drug Saf. 1997;17(6):374–389.
   PubMed Web of Science ®Google Scholar
• Strom BL. What is Pharmacoepidemiology?. In: Strom BL, editor. Pharmacoepidemiology. 4th ed. Chichester: John Wiley & Sons, Ltd. doi:10.1002/9780470059876.ch1
   Google Scholar
• Kelly WN, Arellano FM, Barnes J, et al. Guidelines for submitting adverse event reports for publication. Pharmacoepidemiol Drug Saf. 2007;16(5):581–587.
   PubMed Web of Science ®Google Scholar
• Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–245.
   PubMed Web of Science ®Google Scholar
• Kramer MS, Leventhal JM, Hutchinson TA, et al. An algorithm for the operational assessment of adverse drug reactions. I. Background, description, and instructions for use. Jama. 1979;242(7):623–632.
   PubMed Web of Science ®Google Scholar
• Bégaud B, Evreux JC, Jouglard J, et al. Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France. Thérapie. 1985;40(2):111–118.
   PubMed Web of Science ®Google Scholar
• Agbabiaka TB, Savović J, Ernst E. Methods for causality assessment of adverse drug reactions: a systematic review. Drug Saf. 2008;31(1):21–37.
   PubMed Web of Science ®Google Scholar
• Horn JR, Hansten PD, Chan L-N. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother. 2007;41(4):674–680.
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ. The pharmacovigilance syndrome. J Clin Psychopharmacol. 2015;35(4):361–363.
   PubMed Web of Science ®Google Scholar
• Villier C, Schir E, Mallaret M Effets indésirables du baclofène dans le traitement des addictions Suivi national de pharmacovigilance [Adverse drug reactions of baclofen in the treatment of addictive disorders]. Comité technique de Pharmacovigilance. 2012 [cited 2016 Feb 10]. Available from: https://ansm.sante.fr/…/2/…/baclofene–suivi-pharmacovigilance-2011.pdf
   Google Scholar
• Agence Nationale de Sécurité du Médicament et des produits de santé (ANSM). Rapport du Comité Technique de Pharmacovigilance [Report of the Pharmacovigilance Technical Committee]. Comité Technique de Pharmacovigilance. 2013 [cited 2016 Feb 10]. Available from: http://ansm.sante.fr/content/download/52485/676187/version/2/file/CR_CT012013023_Pharmacovigilance.pdf
   Google Scholar
• Kiel LB, Hoegberg LCG, Jansen T, et al. A nationwide register-based survey of baclofen toxicity. Basic Clin Pharmacol Toxicol. 2015;116(5):452–456.
   PubMed Web of Science ®Google Scholar
• Pape E, Roman E, Scala-Bertola J, et al. Death of an alcohol-dependent patient following intentional drug intoxication: implication of baclofen? Eur Addict Res. 2014;20(6):300–304.
   PubMed Web of Science ®Google Scholar
• Yelnik AP, Sportouch P, Questel F. Flaccid paralysis due to chronic baclofen overdosage. Alcohol Alcohol. 2013;48(3):375.
   PubMed Web of Science ®Google Scholar
• Franchitto N, Pelissier F, Lauque D, et al. Self-intoxication with baclofen in alcohol-dependent patients with co-existing psychiatric illness: an emergency department case series. Alcohol Alcohol. 2014;49(1):79–83.
   PubMed Web of Science ®Google Scholar
• Soufia M, Plaze M, Gueguen B, et al. Behavioral disinhibition with baclofen. J Clin Psychopharmacol. 2010;30(6):759–760.
   PubMed Web of Science ®Google Scholar
• Geoffroy PA, Auffret M, Deheul S, et al. Baclofen-induced manic symptoms: case report and systematic review. Psychosomatics. 2014;55(4):326–332.
   PubMed Web of Science ®Google Scholar
• Auffret M, Rolland B, Deheul S, et al. Severe tinnitus induced by off-label baclofen. Ann Pharmacother. 2014;48(5):656–659.
   PubMed Web of Science ®Google Scholar
• Perogamvros L, Pépin JL, Thorens G, et al. Baclofen-associated onset of central sleep apnea in alcohol use disorder: a case report. Respir Int Rev Thorac Dis. 2015. doi:10.1159/000439542.
   Google Scholar
• Gégu C, Gagnon N, Schmitt C, et al. High-dose baclofen treatment-induced overdose in a chronic ethylic patient with renal insufficiency. Thérapie. 2012;67(6):529–531.
   PubMed Web of Science ®Google Scholar
• Macaigne G, Champagnon N, Harnois F, et al. Baclofen-induced acute hepatitis in alcohol-dependent patient. Clin Res Hepatol Gastroenterol. 2011;35(5):420–421.
   PubMed Web of Science ®Google Scholar
• Rolland B, Jaillette E, Carton L, et al Assessing alcohol versus baclofen withdrawal syndrome in patients treated with baclofen for alcohol use disorder. J Clin Psychopharmacol. 2014;34(1):153–156.
   PubMed Web of Science ®Google Scholar
• Reichmuth P, Blanc A-L, Tagan D. Unintentional baclofen intoxication in the management of alcohol use disorder. BMJ Case Rep. 2015;2015. doi:10.1136/bcr-2015-212187.
   PubMedGoogle Scholar
• Bence C, Cottencin O, Deheul S, et al. Baclofen-induced edema in alcohol use disorders. J Clin Pharmacol. 2014;54(4):478–481.
   PubMed Web of Science ®Google Scholar
• Rolland B, Deheul S, Danel T, et al. A case of de novo seizures following a probable interaction of high-dose baclofen with alcohol. Alcohol Alcohol. 2012;47(5):577–580.
   PubMed Web of Science ®Google Scholar
• Clarisse H, Imbert B, Belzeaux R, et al. Baclofen and risperidone association increases dramatically triglycerides level. Alcohol Alcohol. 2013;48(4):515–516.
   PubMed Web of Science ®Google Scholar
• Hasin D, Kilcoyne B. Comorbidity of psychiatric and substance use disorders in the United States: current issues and findings from the NESARC. Curr Opin Psychiatry. 2012;25(3):165–171.
   PubMed Web of Science ®Google Scholar
• Rolland B, Valin T, Langlois C, et al. Safety and drinking outcomes among patients with comorbid alcohol dependence and borderline personality disorder treated with high-dose baclofen: a comparative cohort study. Int Clin Psychopharmacol. 2015;30(1):49–53.
   PubMed Web of Science ®Google Scholar
• Sobell LC, Sobell MB. Timeline Follow-back: a technique for assessing self-reported ethanol consumption. In: Allen J, Litten RZ, editors. Measuring alcohol consumption: psychosocial and biological methods. Totowa, NJ: Humana Press; 1992. p. 41–72.
   Google Scholar
• Hoeksema HL, De Bock GH. The value of laboratory tests for the screening and recognition of alcohol abuse in primary care patients. J Fam Pract. 1993;37(3):268–276.
   PubMed Web of Science ®Google Scholar
• Marsot A, Imbert B, Alvarez JC, et al. High variability in the exposure of baclofen in alcohol-dependent patients. Alcohol Clin Exp Res. 2014;38(2):316–321.
   PubMed Web of Science ®Google Scholar
• Imbert B, Alvarez JC, Simon N. Anticraving effect of baclofen in alcohol-dependent patients. Alcohol Clin Exp Res. 2015;39(9):1602–1608.
   PubMed Web of Science ®Google Scholar
• Rolland B, Paille F, Gillet C, et al. Pharmacotherapy for alcohol dependence: the 2015 recommendations of the French alcohol society, issued in partnership with the European Federation of Addiction Societies. CNS Neurosci Ther. 2016;22:25–37. doi:10.1111/cns.12489.
   PubMed Web of Science ®Google Scholar
• Agence Nationale de Sécurité du Médicament et des produits de santé (ANSM). Commission évaluation initiale du rapport entre les bénéfices et les risques des produits de santé. Compte rendu de la séance du 9 juillet 2015. [Commission for the assessment of the risk-benefit ratio of health products. Review of the session of 9 July 2015]. [cited 2016 Feb 10]. Available from: http://ansm.sante.fr/var/ansm_site/storage/original/application/5f5e1e861a2594c72683211ea35fca42.pdf
   Google Scholar